Cargando…

Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma

INTRODUCTION: Recent data from the COMPARZ study seem to suggest a non-inferiority of pazopanib confronted with sunitinib in PFS and OS. We previously reported how VEGF and VEGFR polymorphisms might have a predictive role in patients treated with first-line sunitinib. Aim of our study was to investi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bianconi, Maristella, Faloppi, Luca, Loretelli, Cristian, Zizzi, Antonio, Giampieri, Riccardo, Bittoni, Alessandro, Andrikou, Kalliopi, Prete, Michela Del, Burattini, Luciano, Montironi, Rodolfo, Scartozzi, Mario, Cascinu, Stefano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5122335/ https://www.ncbi.nlm.nih.gov/pubmed/27175586 http://dx.doi.org/10.18632/oncotarget.9229

Ejemplares similares

VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib
por: Scartozzi, M, et al.
Publicado: (2013)

Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients
por: Giampieri, Riccardo, et al.
Publicado: (2016)

Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New
por: Faloppi, Luca, et al.
Publicado: (2016)

Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis
por: Bittoni, Alessandro, et al.
Publicado: (2015)

The Role of LDH Serum Levels in Predicting Global Outcome in HCC Patients Undergoing TACE: Implications for Clinical Management
por: Scartozzi, Mario, et al.
Publicado: (2012)

The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy
por: Faloppi, Luca, et al.
Publicado: (2016)

Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab
por: Scartozzi, Mario, et al.
Publicado: (2012)

Role of Vascular Endothelial Growth Factor (VEGF) and VEGF-R Genotyping in Guiding the Metastatic Process in pT4a Resected Gastric Cancer Patients
por: Scartozzi, Mario, et al.
Publicado: (2012)

Cancer Stem Cell Gene Profile as Predictor of Relapse in High Risk Stage II and Stage III, Radically Resected Colon Cancer Patients
por: Giampieri, Riccardo, et al.
Publicado: (2013)

Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients
por: Scartozzi, M, et al.
Publicado: (2012)

Prognostic Value for Incidental Antihypertensive Therapy With β-Blockers in Metastatic Colorectal Cancer
por: Giampieri, Riccardo, et al.
Publicado: (2015)

Clinical Evidence for Three Distinct Gastric Cancer Subtypes: Time for a New Approach
por: Bittoni, Alessandro, et al.
Publicado: (2013)

Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab
por: Giampieri, Riccardo, et al.
Publicado: (2015)

The role of Micro-RNAs in Hepatocellular Carcinoma: From Molecular Biology to Treatment
por: D’Anzeo, Marco, et al.
Publicado: (2014)

Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management
por: Del Prete, Michela, et al.
Publicado: (2015)

The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management
por: Faloppi, Luca, et al.
Publicado: (2014)

The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib
por: Faloppi, Luca, et al.
Publicado: (2015)

Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells
por: Santoni, M, et al.
Publicado: (2013)

Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter
por: Bianconi, Maristella, et al.
Publicado: (2019)

Neoadjuvant Therapy in Pancreatic Cancer: An Emerging Strategy
por: Bittoni, Alessandro, et al.
Publicado: (2014)

Induction of trismus by sunitinib and pazopanib in metastatic renal cell carcinoma
por: Iyer, Ridhima, et al.
Publicado: (2017)

Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology
por: Aprile, Giuseppe, et al.
Publicado: (2015)

Factors involved in treatment preference in patients with renal cancer: pazopanib versus sunitinib
por: Mitchell, Catherine C, et al.
Publicado: (2014)

Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib
por: Gotink, Kristy J., et al.
Publicado: (2015)

Metformin Use and the Outcome of Metastatic Renal Cell Carcinoma Treated with Sunitinib or Pazopanib
por: Fiala, Ondřej, et al.
Publicado: (2021)

Biological Role of Pazopanib and Sunitinib Aldehyde Derivatives in Drug-Induced Liver Injury
por: Maillard, Maud, et al.
Publicado: (2022)

Neutrophil-to-lymphocyte ratio may be associated with the outcome in patients with prostate cancer
por: Minardi, Daniele, et al.
Publicado: (2015)

Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom
por: Amdahl, Jordan, et al.
Publicado: (2017)

Prognostic impact of mismatch repair genes germline defects in colorectal cancer patients: are all mutations equal?
por: Maccaroni, Elena, et al.
Publicado: (2015)

Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients
por: Scartozzi, M, et al.
Publicado: (2011)

IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma
por: Xu, C-F, et al.
Publicado: (2015)

Efficacy of pazopanib and sunitinib in advanced axial chordoma: a single reference centre case series
por: Lipplaa, Astrid, et al.
Publicado: (2016)

From CENTRAL to SENTRAL (SErum aNgiogenesis cenTRAL): Circulating Predictive Biomarkers to Anti-VEGFR Therapy
por: Giampieri, Riccardo, et al.
Publicado: (2020)

Imatinib, sunitinib and pazopanib: From flat‐fixed dosing towards a pharmacokinetically guided personalized dose
por: Westerdijk, Kim, et al.
Publicado: (2020)

Real-World Treatment Patterns and Costs for Patients with Renal Cell Carcinoma Initiating Treatment with Sunitinib and Pazopanib
por: MacLean, Elizabeth, et al.
Publicado: (2016)

Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis
por: Scartozzi, Mario, et al.
Publicado: (2010)

Metastatic Alveolar Soft Part Sarcoma Responsive to Pazopanib after Progression through Sunitinib and Bevacizumab: Two Cases
por: Read, William L., et al.
Publicado: (2016)

Sunitinib versus Pazopanib Dilemma in Renal Cell Carcinoma: New Insights into the In Vitro Metabolic Impact, Efficacy, and Safety
por: Amaro, Filipa, et al.
Publicado: (2022)

Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma
por: Piva, Francesco, et al.
Publicado: (2015)

Retrospective Cohort Study of Caveolin-1 Expression as Prognostic Factor in Unresectable Locally Advanced or Metastatic Pancreatic Cancer Patients
por: Bittoni, Alessandro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e2f4ucc34nkq95o39rphl9vaqs